Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
The Woodlands, Texas, July 27, 2022– Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Failure | New Drug Applications